Case Reports in Infectious Diseases

Case Reports in Infectious Diseases / 2016 / Article

Case Report | Open Access

Volume 2016 |Article ID 1725287 |

F. AlMutawa, D. Leto, Z. Chagla, "Disseminated Cryptococcal Disease in Non-HIV, Nontransplant Patient", Case Reports in Infectious Diseases, vol. 2016, Article ID 1725287, 4 pages, 2016.

Disseminated Cryptococcal Disease in Non-HIV, Nontransplant Patient

Academic Editor: Pere Domingo
Received22 Jul 2016
Revised15 Oct 2016
Accepted17 Oct 2016
Published09 Nov 2016


Disseminated cryptococcal infection carries a high risk of morbidity and mortality. Typical patients include HIV individuals with advanced immunosuppression or solid organ or hematopoietic transplant recipients. We report a case of disseminated cryptococcal disease in a 72-year-old male who was immunocompromised with chronic lymphocytic leukemia and ongoing chemotherapy. The patient presented with a subacute history of constitutional symptoms and headache after he received five cycles of FCR chemotherapy (fludarabine/cyclophosphamide/rituximab). Diagnosis of disseminated cryptococcal disease was made based on fungemia in peripheral blood cultures with subsequent involvement of the brain, lungs, and eyes. Treatment was started with liposomal amphotericin, flucytosine, and fluconazole as induction. He was discharged after 4 weeks of hospitalization on high dose fluconazole for consolidation for 2 months, followed by maintenance therapy.

1. Introduction

Cryptococcus is environmental yeast found worldwide. Two recognized separate species cause the bulk of disease, Cryptococcus neoformans and C. gattii [1]. There are five different serotypes recognized within these two species. Serotype A is known as C neoformans var. grubii. Serotype D is C. neoformans var. neoformans. Serotypes B and C are recognized as the C. gattii species [2].

Cryptococcus neoformans is found in wild bird and pigeon droppings. It is a significant cause of morbidity and mortality in immunocompromised patients. It mainly infects the HIV positive or transplant recipient population. Other risk factors include the use of high dose steroids, sarcoidosis, and malignancies particularly hematological [3]. Infection is acquired by inhalation of fungal elements from the contaminated soil and is often asymptomatic in normal hosts. Symptomatic disease tends to occur with respiratory symptoms, constitutional symptoms, and a subacute meningitis. We present a case of disseminated cryptococcal disease in a non-HIV, nontransplant patient with good clinical outcomes.

2. Case Presentation

A 72-year-old gentleman presented to hospital for assessment. He had a past medical history significant for chronic lymphocytic leukemia diagnosed 7 years prior to this presentation. He received three cycles of FCR chemotherapy (fludarabine/cyclophosphamide/rituximab), but this was discontinued in the fall of 2013 due to autoimmune hemolytic anemia. He also developed idiopathic thrombocytopenic purpura (ITP) and eventually began a new chemotherapy regimen including cyclophosphamide/vincristine and prednisone. Five cycles into this regimen he developed fevers, night sweats with cough, and mild headaches, without neurologic symptoms. The patient was admitted to the hospital, blood cultures revealed yeast, and caspofungin was started for presumed candidemia. Chest X-ray was normal. When the yeast was identified as Cryptococcus neoformans, liposomal amphotericin was started. The identification was based on colonial morphology, capsules seen on India ink, urea test positivity, and MALDI TOF. The initial serum cryptococcal antigen was 1 : 128. His CT chest revealed miliary nodules scattered throughout both lungs with the suggestion of cryptococcal pulmonary infection (Figure 1). CT head showed no focal lesions and symmetric ventricles, with no evidence of hydrocephalus. Lumbar puncture was performed showing normal protein, nucleated cell count 5 with 19 neutrophils and 80 lymphocytes, and positive cryptococcal antigen with a titre 1 : 1, with negative gram stain, bacterial culture, acid fast bacilli stain and TB culture, virology PCR (enterovirus, HSV 1 and 2, VZV), and HIV serology. He had evidence of retinitis bilaterally when assessed by ophthalmology. Flucytosine (100 mg/Kg per day in 4 divided doses) and fluconazole (for eye involvement) were added, in addition to liposomal amphotericin at 6 mg/Kg dose. In hospital he had mild increased ICP (opening pressure between 35–40), with serial therapeutic lumbar punctures. He developed thrombocytopenia approximately 4 weeks into his admission, leading to cessation of amphotericin and flucytosine, with a transition to fluconazole monotherapy. He was discharged after 4 weeks of hospitalization on high dose fluconazole and 800 mg po daily for consolidation for 2 months, followed by 400 mg po daily for maintenance therapy for 1 year. His cryptococcal antigen titers decreased gradually to negative as shown in Table 1. He continues to be on fluconazole 200 mg po daily indefinitely while remaining on prednisone for ITP. A follow-up CT chest done after the 1-year maintenance therapy showed interval resolution of the miliary nodules.

Serum cryptococcal titreSpinal fluid cryptococcal titre

May 20141 : 128May 20141 : 1
June 20141 : 64June 2014Negative
July 20141 : 64July 2014Negative
August 20141 : 32
November 20141 : 16
February 20151 : 4
April 2015Negative

3. Discussion

As mentioned above, C. neoformans affects mainly immunocompromised individuals worldwide. Serotype A is most commonly isolated, but serotype D is isolated more commonly in European countries [1]. C. gattii mainly affects immunocompetent people in endemic areas in Australia and Papua New Guinea. Clusters were also reported in British Columbia and in the United States Pacific Northwest. In certain areas such as parts of sub-Saharan Africa, about 10% of HIV cases are infected with C. gattii [4]. The infection starts when the fungus is inhaled into the lungs. Infection then spreads to other organs by the circulatory system, mainly to the brain and meninges. Less frequently, other organs such as bones, joints, and skin can be involved. In patients who are not infected with HIV, the disease may occur if they have underlying immunosuppressive conditions, such as Cushing’s syndrome, sarcoidosis, hematological malignancies (leukemia or lymphomas), receipt of TNF inhibitors, or organ transplant [2]. Cryptococcal meningitis is a life-threatening infection and requires immediate clinical attention [5].

Cryptococcal polysaccharide antigen can be detected in both serum and CSF. The antigen detection test is very accurate for invasive disease diagnosis [6]. It is nearly 100% sensitive and 96–99.5% specific when serum is tested and 96–100% sensitive and 93.5–99.8% specific on CSF [7]. Amphotericin B is the first line drug for treatment of cryptococcal meningitis. Flucytosine is added to amphotericin B to decrease the rates of treatment failure in severe meningitis, and it is shown to have survival benefit as well [8, 9]. Since fluconazole can penetrate very well into the CSF as indicated in clinical trials, it is used for both the consolidation and suppressive phases of treatment [10, 11]. Fluconazole, however, is not recommended for the induction phase when a polyene can be used as it only has fungistatic activity. It can be used in combination with amphotericin B at 800 mg/day dosing for induction when flucytosine is not available [12].

Non-HIV infected patients are treated with amphotericin B with or without initial flucytosine for 4 weeks for treatment induction. Patients then can receive fluconazole at 400–800 mg/day for 8 weeks for the consolidation phase. The fluconazole dose is then decreased to 200 mg/day for the suppressive phase. Currently there are no well-defined criteria for stopping treatment. Generally, therapy can be stopped when symptoms improve, with a minimum of 2 negative CSF cultures with normal glucose level, or after 6 months to one year of being asymptomatic. Most patients will remain on fluconazole suppressive therapy for at least 6–12 months to prevent relapse, as studies found a 15%–25% relapse rate in the first year after therapy is discontinued [5]. Controlling the patient’s underlying disease is the most important factor in prognosis. Non-HIV, nontransplant recipient patients have the worst prognosis, typically due to a delay in diagnosis [13]. It is important to identify patients with high risk for relapse or failure in order to design a specific or prolonged antifungal regimen for their treatment course.

A literature review of the reported cases on disseminated cryptococcal neoformans infection in HIV negative patients between 2010 and 2015 is presented in Table 2. Most patients are males with underlying immunosuppression such as transplant and hematological malignancy. Patients received different modalities of treatment in this review as shown in the table. Outcome varies between resolution, relapse, and death.

AgeSexUnderlying conditionPresentationMicrobiologyTreatmentOutcomeReferences

62MaleRenal transplant on cyclosporine, azathioprine, and prednisoneMiliary pulmonary cryptococcusPositive blood culturesFluconazoleDid well and stable[14]
43MaleRenal transplant on cyclosporine, mycophenolate mofetil, and prednisoneCellulitisPositive blood culturesAmphotericin lipid complex at 6 mg/Kg for 2 weeks and then fluconazole for 3 monthsNo recurrence at 4-month follow-up[15]
34MaleNephrotic syndrome on prednisoneBilateral LL ulcersBlood, sputum, and biopsy culturesFluconazoleDeath[16]
26FemaleNo significant past history Crohn’s diseaseColon and sputumFluconazole for 5 weeksImproved[17]
7MaleNo significant past historyHepatosplenomegaly, LAP, bilateral choroiditis, and skin lesionsBlood, CSF, and skin biopsy culturesAmphotericin and fluconazoleRemission[18]
79MaleCOPD and CADSplenomegaly, LAP, and respiratory symptomsSputum cultures and bone marrow PCRAmphotericin and fluconazoleDeath[19]
28MaleNo significant past historyHepatosplenomegaly, LAP, and lymphopeniaLymph node biopsy cultureAmphotericin and fluconazoleDeath[20]
70MaleNo significant past historyThigh nodule, chest, and brain lesionsBiopsy of thigh nodule and sputum culturesAmphotericin and
Resolution of his symptoms and lesions at 1-year follow-up[21]
65FemaleNHL on CHOP- rituximabMeningitis and respiratory symptomsBlood, pleural fluid, and CSF culturesAmphotericin, flucytosine, and
63MaleDiabetes mellitus, AHA-steroid, and splenectomyHeadache, photophobia, decreased vision, panuveitis, and lung/brain lesionsLung biopsy cultureAmphotericin, flucytosine, and
fluconazole for 1 year

LAP, lymphadenopathy; NHL, non-Hodgkin’s lymphoma; CHOP, C: cyclophosphamide, H: doxorubicin hydrochloride (adriamycin), and O: vincristine (Oncovin); PCR, polymerase chain reaction; mg, milligrams; Kg, kilograms.

In summary, we present a non-HIV, nontransplant, immunosuppressed individual with CLL and chemotherapy with disseminated cryptococcal disease involving eyes, brain, and lungs, with positive blood cultures. He was treated with amphotericin, flucytosine, and fluconazole, with a transition to fluconazole consolidation and maintenance therapy, which the patient currently remains on. Disseminated cryptococcal infection is a potential cause of serious morbidity and mortality. It can affect both immunocompromised and immunocompetent people. Delayed diagnosis in unusual hosts, such as the non-HIV, nontransplant population, may lead to unfavourable outcomes.

Competing Interests

The authors declare no competing interests.


F. AlMutawa receives support from Saudi Ministry of Education.


  1. M. Bovers, F. Hagen, and T. Boekhout, “Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex,” Revista Iberoamericana de Micología, vol. 25, no. 1, pp. S4–S12, 2008. View at: Google Scholar
  2. S. A. Howell, K. C. Hazen, and M. E. Brandt, “Candida, Cryptococcus, and other yeasts of medical importance,” in Mannual of Clinical Microbiology, J. H. Jorgensen and M. A. Pfaller, Eds., pp. 1984–2014, ASM Press, Washington, DC, USA, 2015. View at: Google Scholar
  3. B. J. Park, K. A. Wannemuehler, B. J. Marston, N. Govender, P. G. Pappas, and T. M. Chiller, “Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS,” AIDS, vol. 23, no. 4, pp. 525–530, 2009. View at: Publisher Site | Google Scholar
  4. A. P. Litvintseva, J. Xu, and T. G. Mitchell, “Population structure and ecology of Cryptococcus neoformans and Cryptococcus Gattii,” in Cryptococcus: From Human Pathogen to Model Yeast, J. Hietman, Tr. Kozel, K. J. Kwon-Chung, J. R. Perfect, and A. Casadevall, Eds., pp. 97–111, ASM Press, Washington, DC, USA, 2010. View at: Google Scholar
  5. J. R. Perfect, “Cryptococcosis (Cryptococcus neoformans and Cryptococcus gattii),” in Principles and Practice of Infectious Diseases, J. E. Bennett, R. Dolin, and M. J. Blaser, Eds., pp. 2934–2948, Elsevier Saunders, Philadelphia, Pa, USA, 2015. View at: Google Scholar
  6. C. A. Kauffman, A. G. Bergman, P. J. Severance, and K. D. McClatchey, “Detection of cryptococcal antigen. Comparison of two latex agglutination tests,” American Journal of Clinical Pathology, vol. 75, no. 1, pp. 106–109, 1981. View at: Publisher Site | Google Scholar
  7. J. R. Perfect, W. E. Dismukes, F. Dromer et al., “Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 291–322, 2010. View at: Publisher Site | Google Scholar
  8. F. Dromer, C. Bernede-Bauduin, D. Guillemot, and O. Lortholary, “Major role for amphotericin B-flucytosine combination in severe cryptococcosis,” PLoS ONE, vol. 3, no. 8, article e2870, 2008. View at: Publisher Site | Google Scholar
  9. J. N. Day, T. T. H. Chau, M. Wolbers et al., “Combination antifungal therapy for cryptococcal meningitis,” The New England Journal of Medicine, vol. 368, pp. 1291–1302, 2013. View at: Publisher Site | Google Scholar
  10. S. A. Bozzette, R. A. Larsen, J. Chiu et al., “A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group,” The New England Journal of Medicine, vol. 324, no. 9, pp. 580–584, 1991. View at: Publisher Site | Google Scholar
  11. W. G. Powderly, M. S. Saag, G. A. Cloud et al., “A Controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 326, no. 12, pp. 793–798, 1992. View at: Publisher Site | Google Scholar
  12. P. G. Pappas, P. Chetchotisakd, R. A. Larsen et al., “A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1775–1783, 2009. View at: Publisher Site | Google Scholar
  13. E. W. Bratton, N. El Husseini, C. A. Chastain et al., “Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and hiv-negative/non-transplant,” PLoS ONE, vol. 7, no. 8, article e43582, 2012. View at: Publisher Site | Google Scholar
  14. C. B. Severo, R. M. Bruno, F. de Mattos Oliveira, P. Z. Teixeira, B. Hochhegger, and L. C. Severo, “A case of miliary pulmonary cryptococcosis and review of literature,” Mycopathologia, vol. 179, no. 3-4, pp. 313–315, 2015. View at: Publisher Site | Google Scholar
  15. R. Chaya, S. Padmanabhan, V. Anandaswamy, and A. Moin, “Disseminated cryptococcosis presenting as cellulitis in a renal transplant recipient,” Journal of Infection in Developing Countries, vol. 7, no. 1, pp. 60–63, 2013. View at: Google Scholar
  16. W. Ni, Q. Huang, and J. Cui, “Disseminated cryptococcosis initially presenting as cellulitis in a patient suffering from nephrotic syndrome,” BMC Nephrology, vol. 14, no. 1, article 20, 2013. View at: Publisher Site | Google Scholar
  17. G. Sciaudone, G. Pellino, I. Guadagni, A. Somma, F. P. D'Armiento, and F. Selvaggi, “Disseminated Cryptococcus neoformans infection and Crohn's disease in an immunocompetent patient,” Journal of Crohn's and Colitis, vol. 5, no. 1, pp. 60–63, 2011. View at: Publisher Site | Google Scholar
  18. B. B. Jain, D. Bose, R. Mondal, and S. Chattopadhyay, “Disseminated cryptococcosis in an immunocompetent child,” Turkish Journal of Pathology, vol. 1, no. 1, 2013. View at: Publisher Site | Google Scholar
  19. M. B. Abid, S. De Mel, and M. P. Limei, “Disseminated Cryptococcal infection in an immunocompetent host mimicking plasma cell disorder: a case report and literature review,” Clinical Case Reports, vol. 3, no. 5, pp. 319–324, 2015. View at: Publisher Site | Google Scholar
  20. G. Santra, “Disseminated cryptococcosis in a case of idiopathic CD4+ lymphocytopenia,” Journal of the Association of Physicians of India, vol. 55, pp. 527–528, 2007. View at: Google Scholar
  21. S. Suchitha, C. S. Sheeladevi, R. Sunila, and G. V. Manjunath, “Disseminated cryptococcosis in an immunocompetent patient: a case report,” Case Reports in Pathology, vol. 2012, Article ID 652351, 3 pages, 2012. View at: Publisher Site | Google Scholar
  22. Y. Hirai, Y. Ainoda, T. Shoji et al., “Disseminated cryptococcosis in a Non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review,” Mycopathologia, vol. 172, no. 3, pp. 227–232, 2011. View at: Publisher Site | Google Scholar
  23. Z. A. Kresch, D. Espinosa-Heidmann, T. Harper, and G. J. Miller, “Disseminated Cryptococcus with ocular cryptococcoma in a human immunodeficiency virus-negative patient,” International Ophthalmology, vol. 32, no. 3, pp. 281–284, 2012. View at: Publisher Site | Google Scholar

Copyright © 2016 F. AlMutawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.